Improvement of the inhibitory effect of xanthones on NO production by encapsulation in PLGA nanocapsules by Teixeira, M et al.
Improvement of the inhibitory effect of xanthones on NO production
by encapsulation in PLGA nanocapsules
MARIBEL TEIXEIRA1,2, FA´TIMA CERQUEIRA1, CARLOS MAURI´CIO BARBOSA3,4,
MARIA SA˜O JOSE´ NASCIMENTO1,5, & MADALENA PINTO1,6
1CEQOFFUP—Centro de Estudos de Quı´mica Orgaˆnica, Fitoquı´mica e Farmacologia da Universidade do Porto, Faculdade de
Farma´cia, Universidade do Porto, R. Anı´bal Cunha, 164, 4050-047 Porto, Portugal, 2Instituto Superior de Cieˆncias da Sau´de-
Norte, R. Central de Gandra, 1317, 4585-116 Gandra, Paredes, Portugal, 3CTMUP—Servic¸o de Tecnologia Farmaceˆutica,
Faculdade de Farma´cia, Universidade do Porto, R. Anı´bal Cunha, 164, 4050-047 Porto, Portugal, 4CETMED—Centro
Tecnolo´gico do Medicamento, R. do Passeio Alegre, 840, 4150–574 Porto, Portugal, 5Servic¸o de Microbiologia, Faculdade de
Farma´cia, Universidade do Porto, R. Anı´bal Cunha, 164, 4050-047 Porto, Portugal, and 6Servic¸o de Quı´mica Orgaˆnica,
Faculdade de Farma´cia, Universidade do Porto, R. Anı´bal Cunha, 164, 4050-047 Porto, Portugal
Abstract
For the first time the inhibitory effect of xanthone and 3-methoxyxanthone on nitric oxide (NO) production by IFN-g /LPS
activated J774 macrophage cell line is reported. A remarkable improvement of this effect promoted by encapsulation of these
compounds in nanocapsules of poly (DL-lactide-co-glycolide) (PLGA) is also demonstrated. A weak inhibitory effect of 3.6%
on NO production by activated macrophages was observed for xanthone at the highest studied concentration (100mM).
This effect was slightly higher for 3-methoxyxanthone at the same concentration, producing a reduction of 16.5% on NO
production. In contrast, equivalent concentrations of xanthone and 3-methoxyxanthone incorporated in nanocapsules
produced a significant decrease on NO production of 91.8 and 80.0%, respectively. Empty nanocapsules also exhibited a
slight NO inhibitory activity, which may be due to the presence of soybean lecithin in the composition of the nanosystems.
The viability of the macrophages was not affected either by free or nanoencapsulated xanthones. Fluorescence microscopy
analysis confirmed that a phagocytic process was involved in the macrophage uptake of xanthone- and 3-methoxyxanthone-
loaded PLGA nanocapsules. Phagocytosis might be the main mechanism responsible for the enhancement of the intracellular
delivery of both compounds and consequently for the improvement of their biological effect.
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Introduction
Nitric oxide (NO) is a gas produced by constitutive
and inducible isoforms of NO synthase (NOS) from
L-arginine and molecular oxygen in a variety of cells
(Gross and Wollin 1995, Aramaki 2000). Constitu-
tive NOS isoforms are expressed in endothelial and
neuronal cells and are calcium- and calmudolin-
dependent (Kolb and Kolb-Bachofen 1992, Aramaki
2000). NO produced by these NOS acts as an
intracellular messenger. In contrast, the inducible
NOS isoform (iNOS) is not dependent on calcium or
calmudolin and its expression is induced by
immunological stimuli in virtually all nucleated
mammalian cells (Gross and Wollin 1995). Activation
of macrophages with some cytokines and/or with
lipopolysaccharide (LPS) induces the production
of large quantities of NO generated by iNOS
(Lowenstein et al. 1993, Gross and Wollin 1995).
NO regulates several important physiological pro-
cesses, namely the maintenance of normal blood
pressure, neuronal mediation and inflammatory res-
ponses and also acts as a defensive agent by damaging
pathogenic DNA (Kuo and Schoeder 1995). How-
ever, excessive and unregulated NO synthesis has
been implicated as causal or contributing to
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pathophysiological conditions, including many lethal
and debilitating diseases of humans, such as vascular
shock, stroke, diabetes, arthritis and chronic inflam-
mation (Gross and Wollin 1995).
Xanthones ( ¼ 9H-xanthen-9-ones) are heterocyclic
compounds based on the dibenzo-g-pirone nucleus
(Figure 1) including natural, semi synthetic and totally
synthetic structures. Xanthones have extensive bio-
logical activities such as hepatoprotection, anti-
inflammation, immunomodulation, growth inhibition
of human cancer cell lines and modulation of protein
kinase C (PKC) (Fernandes et al. 1995, Lin et al. 1996,
Pinto and Nascimento 1997, Gonzalez et al. 1999,
Peres et al. 2000, Pedro et al. 2002, Saraiva et al.
2002a,b, Pinto and Sousa 2003, Saraiva et al. 2003).
Nevertheless, studies on reduction of NO production
by xanthone derivatives are scarce. Some data are
reported only for mangiferin, which is a C-glucosyl-
xanthone (Garcı´a et al. 2002, Leiro et al. 2003).
Xanthone and 3-methoxyxanthone (Figure 1) were
already evaluated in our group concerning different
biological activities, namely inhibitory activity of
monoamine oxidase (Thull et al. 1993), immuno-
modulatory (Pinto and Nascimento 1997), PKC
modulation (Saraiva et al. 2002b) and growth
inhibitory activity of human cancer cell lines (Pedro
et al. 2002). In the present work, the inhibitory effect of
these xanthones on the production of NO by the
murine macrophage cell line J774 is reported for the
first time. In order to enhance the intracellular delivery
of the xanthones and thus to improve their biological
activity, both compounds were encapsulated in
biodegradable nanocapsules of poly (DL-lactide-co-
glycolide) (PLGA). In fact, nanoencapsulation is
known to increase the intracellular delivery of several
drugs into phagocytic cells (Morin et al. 1994, Wang
and Zhang 2001). Nanocapsules can be easily obtained
by interfacial deposition of the polymer around an oily
core in which lipid-soluble drugs can be dissolved, as
we have described previously (Teixeira et al. 2004).
PLGA has been selected for nanocapsule preparation,
since polyesters, including poly (lactic acid), poly
(glycolic acid) and their copolymers, have emerged as
the most widely studied class of polymers for
pharmaceutical use due to their biocompatibility and
biodegradability characteristics (Jain et al. 1998).
The main goal of the present study was to evaluate
in vitro the inhibitory effect of xanthone and 3-
methoxyxanthone on NO production by the activated
macrophage cell line J774 as well as to improve that




Xanthone, PLGA (50:50) MW 50,000–75,000,
Pluronic F-68 and soybean lecithin (40% purity by
thin-layer chromatography) were purchased from
Sigma Chemical Co. (St Louis, USA). 3-Methoxy-
xanthone was synthesized in our laboratory by alkaline
cyclization of 2-hydroxy-20,4-dimethoxybenzo-
phenone as previously described (Fernandes et al.
1998). Myritol 318 (caprilic/capric acid triglyceride)
was kindly supplied by Henkel (Lisbon, Portugal).
Foetal bovine serum (FBS) and RPMI-1640 were
purchased from Gibco Invitrogen Co. (Barcelona,
Spain). Other chemicals were of analytical grade
and unless otherwise indicated were purchased
from Sigma.
Preparation and characterization of nanocapsules
Nanocapsules containing either xanthone or 3-meth-
oxyxanthone were prepared as previously described
(Teixeira et al. 2004). Briefly, about 50 mg of PLGA
and 100 mg of soybean lecithin were dissolved in 10 ml
of acetone. Xanthone (7.2 mg) or 3-methoxyxanthone
(16.8 mg) was dissolved in 0.6 ml of Myritol 318 and
the obtained solution was added to the acetonic
solution. The final solution was poured into 20 ml of
an aqueous solution of Pluronic F-68 0.5% (w/v) under
moderate stirring, leading to the formation of
nanocapsules. Acetone was then removed under
vacuum and the colloidal dispersion of nanocapsules
was concentrated to 5 ml by evaporation under
reduced pressure. Non-encapsulated xanthones
(either xanthone or 3-methoxyxanthone) were separ-
ated by ultrafiltration/centrifugation (centrifugal filter
devices Centricon YM-50, Milliporew, Bedford, USA)
at 4000g for 2 h (Beckman UL-80 ultracentrifuge,
Albertville, USA).
Empty nanocapsules were prepared according to
the same procedure but omitting xanthones in the
organic phase. Nanoemulsion (NE) was prepared in
the same way as nanocapsules, but omitting the
polymer and the xanthones. Nanospheres (NS) were
obtained omitting lecithin, Myritol 318 and
xanthones. Lecithin dispersion (LD) was prepared
omitting polymer, Myritol 318 and xanthones.
Myritol 318 aqueous dispersion (MD) was obtained
omitting polymer, lecithin and xanthones. Freshly
prepared formulations were used in all experiments.Figure 1. Chemical structure of xanthones.
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Mean particle size of xanthone- and 3-methoxy-
xanthone-loaded nanocapsules and empty nano-
capsules, determined by photon correlation spectroscopy
(Zetasizer 5000, Malvern Instruments, Malvern, UK)
was 273 ^ 18, 271 ^ 16 and 261 ^ 17 nm, res-
pectively.
The amount of xanthone and 3-methoxyxanthone
in nanocapsules was determined following dissolution
of aliquots of nanocapsule dispersions in acetonitrile
by a previously validated HPLC method (Teixeira et al.
2003). Incorporation efficiency was higher than 77%
for nanocapsule formulations containing either
xanthone or 3-methoxyxanthone.
NO production assay
The murine J774 macrophage cell line was maintained
in RPMI-1640 medium supplemented with 10% heat-
inactivated FBS serum, 2 mM glutamine and
50mg/ml of gentamicin (designated thereafter as
culture medium) at 378C in a 5% CO2 humidified
atmosphere. Cells were added to 96-well flat-bottom
microplates at a density of 0.5 £ 106 cells/ml and
allowed to adhere for 2 h. To induce iNOS, culture
medium was replaced by fresh medium containing
LPS (1mg/ml) and IFN-g (100 U/ml). Aqueous
dispersions of nanocapsules containing xanthone or
3-methoxyxanthone as well as solutions of xanthone
or 3-methoxyxanthone in DMSO were diluted
with culture medium (concentrations ranging from
2 to 100mM) and tested. Equivalent concentrations of
empty nanocapsules were also tested. Final concen-
trations of dimethylsulfoxide (DMSO) showed no
interference with the tested biological activity. Sample
dilutions were added together with stimulus and their
effect on NO production was evaluated after 24 h of
incubation at 378C, quantifying nitrite accumulation
in cell culture supernatant by the Griess reaction
(Green et al. 1982).
NO scavenging assay
Sodium nitroprusside (5 mM) in PBS was mixed with
the different samples (xanthone- and 3-methoxy-
xanthone-loaded nanocapsules, empty nanocapsules
as well as xanthone and 3-methoxyxanthone solutions
in DMSO) and with ethanol/PBS (1:9) and incubated
for 150 min at 258C in 96-well flat-bottom micro-
plates. After incubation, Griess reagent (1% w/v
sulphanilamide and 0.1% w/v naphtylethylenediamide
in 5% v/v phosphoric acid) was added and allowed to
react during 10 min at 258C and the absorbance was
measured at 550 nm. Controls consisted of ethanol/
PBS (for 0% of nitrite production) and sodium
nitroprusside (for 100% of nitrite production). The
eventual interference of the samples with the Griess
reagent was also evaluated, using the same procedure
but omitting the sodium nitroprusside. Scavenging
activity, determined in terms of percentage of nitrite
formation, was present when the percentage of nitrite
formed in the presence of the sample was less than
70% of the sodium nitroprusside control (De las
Heras 1997).
Macrophage viability
To evaluate the eventual toxicity of both xanthones
and the respective nanocapsule formulations on
J774 macrophages the MTT-assay was used (Moss-
man 1983). This assay measures the ability of viable
cells to reduce the tetrazolium salt of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoium bro-
mide (MTT) to formazan. Briefly, macrophages
plated in 96-well flat-bottom microplates were
activated with IFN-g/LPS and exposed for 24 h to
serial concentrations of the different samples.
Following this incubation period, the MTT solution
(1 mg/ml) was added. After 4 h of incubation,
formazan was solubilized overnight at 378C in a
sodium lauryl sulfate/N,N-dimethylformamide
(SDS/DMF) solution (20% SDS in a 50% solution
of DMF, pH 4.7). Absorbance of the coloured
solution was measured at 550 nm. Results were
expressed, as percentage of viable cells compared to
control cells incubated with fresh culture medium
(100% viability). Cell toxicity was considered
when the viability of the exposed cells was less
than 70%.
Uptake of nanocapsules by J774 macrophage cell line
The fluorescence exhibited by xanthone and
3-methoxyxanthone was used to study the cellular
uptake of the respective nanosystems by fluor-
escence microscopy. Macrophages were plated at a
density of 0.5 £ 106 cells/ml onto glass cover slips in
6-well plates and allowed to adhere for 2 h. Then
macrophages were activated with IFN-g/LPS, as
described above and incubated with 100mM of each
nanocapsule formulation for 4 h at 48C or at 378C.
After incubation, cells were washed three times with
PBS and fixed with 4% paraformaldehyde for
10 min at room temperature. Cells were observed
with an Axiovert 200M fluorescence microscope
(Carl Zeiss, Germany) equipped with a filter set
standard for DAPI. The images were acquired with
an Axiocam Camera (Carl Zeiss, Germany) at
different focus positions with intervals of 0.5 mm
and deconvolved with Axiovision LE 4.1 (Carl
Zeiss, Germany).
Statistics
Results are presented as mean values ^ SEM of at
least three experiments. Paired t-test was used
to evaluate the statistical significance of differences.
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P values ,0.05 or ,0.01 were considered statistically
significant. Statistic calculations were performed with
SPSS for Windows (Release 11.5).
Results and discussion
Effect of free and encapsulated xanthones on NO
production
The effect of xanthone, 3-methoxyxanthone and the
respective nanocapsule formulations on NO pro-
duction by the IFN-g/LPS activated murine macro-
phage cell line J774 was evaluated (Figures 2 and 3).
As shown in Figure 2a, NO production was weakly
affected by the presence of free xanthone. In fact,
even at the highest studied concentration (100mM)
the inhibition of NO production was only 3.6%.
In contrast, an equivalent concentration of xanthone
incorporated in nanocapsules produced a signi-
ficant decrease on NO production (91.8%;
P , 0:01). Results also showed that for all tested
concentrations, xanthone-loaded nanocapsules were
always associated with a significant decrease
ðP , 0:05Þ of NO production when compared with
free xanthone.
Comparing Figures 2a and 3a, 3-methoxy-
xanthone showed a higher inhibitory effect on NO
production than xanthone. In fact, a 100mM
concentration of 3-methoxyxanthone caused a
16.5% inhibition of NO production. Moreover, the
incorporation in nanocapsules of an equivalent
concentration of 3-methoxyxanthone caused a
decrease of 80%, showing that, as it was observed
for xanthone, nanoencapsulation of this compound
also leads to a significant ðP , 0:01Þ improvement
of its NO inhibitory effect.
Figure 2. Effect of xanthone (XAN) and xanthone-loaded nanocapsules (XAN Ncs) (2a) and of empty nanocapsules (Empty Ncs) and
xanthone-loaded nanocapsules (XAN Ncs) (2b) on NO production by IFN-g/LPS stimulated J774 macrophages. Results show mean
values ^ SEM ðn ¼ 5Þ: *P , 0.05, **P , 0.01.
Figure 3. Effect of 3-methoxyxanthone (3-MeOXAN) and 3-methoxyxanthone-loaded nanocapsules (3-MeOXAN Ncs) (3a) and of empty
nanocapsules (Empty Ncs) and 3-methoxyxanthone-loaded nanocapsules (3-MeOXAN Ncs) (3b) on NO production by IFN-g/LPS
stimulated J774 macrophages. Results show mean values ^ SEM ðn ¼ 5Þ: *P , 0.05, **P , 0.01.
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Results from Figures 2b and 3b show that empty
nanocapsules also produced an inhibitory effect on
NO production. Nevertheless, the comparison of the
inhibitory activities of empty and xanthones-loaded
nanocapsules showed that these latter were always
associated with a significantly higher NO inhibitory
effect ðP , 0:05Þ: Furthermore, the difference
between the effects of nanocapsules containing
xanthones and empty nanocapsules was significantly
higher ðP , 0:05Þ than the effect of free xanthones.
Thus, an additive effect due to the presence of the
xanthones was accompanied by an effect due to the
nanoencapsulation of the compounds.
NO inhibitory activity detected for all tested
products was not due to a toxic effect, since the J774
activated macrophages exposed to the different
samples always showed cell viability higher than
70%. A direct scavenging activity of NO either by the
tested xanthonic compounds or by the nanocapsule
formulations was also excluded since no NO scaven-
ging activity was observed (data not shown).
In order to investigate which nanocapsule exci-
pients were responsible for the NO inhibitory effect
produced by empty nanocapsules, the following
formulations were prepared: nanoemulsion (NE),
nanospheres (NS), lecithin dispersion (LD), Myritol
318 dispersion (MD) and Pluronic F-68 solution
(PS) (0.5% w/v). Each tested preparation had the
same concentration of the different excipients
present in xanthone-loaded nanocapsules, i.e.
theoretical xanthone concentration equivalent. As
shown in Figure 4 all formulations containing
lecithin, such as empty nanocapsules, NE and LD,
were associated with a reduction of NO production.
Formulations without lecithin produced no
reduction on NO levels. These results indicated
that lecithin could be the excipient responsible for
the inhibitory activity exhibited by empty nanocap-
sules. As it was previously reported by Aramaki et al.
(1996), negatively charged unloaded liposomes
containing phosphatidylserine or phosphatidic acid
also elicited an inhibitory effect on NO production
by macrophages as a result of suppression of NOS
induction. In the present work, soybean lecithin used
for nanocapsule preparation contained approxi-
mately 40% of phosphatidylcholine and other
components, such as phosphatidic acid and phos-
phatidylserine, which might explain the inhibitory
activity exhibited by empty nanocapsules.
The improvement of the inhibitory effect of both
xanthones on NO production through nanoencapsu-
lation could be due to an enhancement of the
intracellular delivery of the compounds, as it was
previously reported for different drugs (Morin et al.
1994, Wang and Zhang 2001). It is well known that
the uptake of nanoparticles by macrophages occurs
mainly by phagocytosis, which affords a specific
targeting of drugs and immunomodulators to this type
of cells (Maaßen et al. 1993, Legrand et al. 1999).
Thus, phagocytosis of nanocapsules followed by
release of the compounds in the lysosomes, as
described by Seyler et al. (1999) for nanocapsules
containing a derivative of muramyldipeptide, might be
the main mechanism by which the intracellular
delivery of xanthone and 3-methoxyxanthone was
promoted. Furthermore, xanthones might also be
transferred by diffusion after adsorption of nano-
capsules onto the cells, or be released into the medium
in the vicinity of cell membrane, generating a local
concentration gradient that would favour the diffusion
into the cells, as it was described by Maaßen et al.
(1993) and Seyler et al. (1999).
Uptake of nanocapsules by J774 macrophage cell line
In order to confirm the occurrence of a phagocytic
process in the internalization of the nanocapsules a
fluorescence microscopy technique was adopted and
performed at different focus positions that allows
identification more clearly if the observed fluorescence
is located inside or outside the cells. Microphotographs
of cells incubated at 378C (Figure 5a1 and b1) showed
Figure 4. Effect of different formulations without xanthones on NO production by IFN-g/LPS stimulated J774 macrophages: Nanocapsules
(NC), nanoemulsion (NE), nanospheres (NS), Pluronic F-68 solution (PS), Myritol 318 dispersion (MD) and lecithin dispersion (LD). Results
show the mean values of three replicates from one representative experiment of two carried out independently.
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intramacrophage blue fluorescence concentrated in
vesicular compartments, corresponding to xanthone-
or 3-methoxyxanthone-loaded nanocapsules. Incu-
bation at 48C resulted in a fluorescence located outside
cells near macrophages surface (Figure 5a2 and b2).
No fluorescence was observed either inside or
outside the macrophages incubated with empty
nanocapsules (results not shown). It is well known
that the ability of macrophages to phagocyte particles
is greatly suppressed at 48C (Tabata and Ikada 1988).
Thus, our results indicate that nanocapsule internal-
ization, observed at 378C, involves a phagocytic
process, whereas at 48C a passive binding of
nanocapsules to macrophage surface may occur.
These results are in accordance with those reported
by Mosqueira et al. (2001) for PLA nanocapsules
containing a fluorescent probe, using the same J774
macrophage cell line.
Conclusions
A weak inhibitory effect on NO production by
LPS/INF-g activated J774 macrophage cell line was
observed for xanthone, even at the highest studied
concentration (100mM). This effect was slightly
higher for 3-methoxyxanthone. The encapsulation of
these compounds in PLGA nanocapsules afforded a
remarkable increase of the inhibitory effect on NO
production. For xanthone-loaded nanocapsules a
decrease of about 90% of NO production was achieved
for 100mM concentration, whereas a reduction of
80% was observed for an equal concentration of 3-
methoxyxanthone-loaded nanocapsules.
Fluorescence microphotographs confirmed that a
phagocytic process was involved in the uptake of
xanthone- and 3-methoxyxanthone-loaded PLGA
nanocapsules by macrophages. Phagocytosis might
be the main responsible mechanism for the enhance-
ment of the intracellular delivery of both xanthones
and consequently for the improvement of their
biological effect.
Although the mechanism by which xanthone and
3-methoxyxanthone inhibits NO production by
activated macrophages is not yet elucidated, the
results presented here suggest that nanocapsule
formulations of these xanthones are promising
systems that might be used in disorders associated
with production of high amounts of NO by
macrophages. Moreover, these results are very
encouraging for further studies concerning the
improvement of other biological activities of xanthone
and its derivatives through their incorporation in
nanoparticles.
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Figure 5. Fluorescent microphotographs of murine macrophage cell line J774 incubated with xanthone nanocapsules (a), and
3-methoxyxanthone nanocapsules (b) at 378C (a1, b1) and 48C (a2, b2) for 4 h.
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